Emergent BioSolutions Inc. (NYSE:EBS)
Stock Price:
$8.10
+0.24
(3.05%)
Updated
Mar 24, 2023 08:00 PM GMT+0000
| Market Cap | 406.14M |
|---|---|
| Revenue | 1.12B |
| Gross Profit | 427.20M |
| Shares Out | 50.14M |
| EPS (ttm) | -4.47 |
| PE Ratio | -1.8147 |
| Forward PE | -9.5070 |
| Dividend Rate (ttm) | 0.0000 |
| Dividend Yield | 0.0000 |
| Trading Day | Mar 24 |
|---|---|
| Last Price | $8.10 |
| Previous Close | $7.86 |
| Change ($) | 0.24 |
| Change (%) | 3.05% |
| Day's Open | 7.77 |
| Day's Range | 7.77 - 8.11 |
| Day's Volume | 1.15M |
| 52 Week Range | 7.74 - 45.14 |
About Emergent BioSolutions Inc.
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through their specialty products and contract development and manufacturing services, the company is dedicated to providing solutions that address public health threats.
Through social responsibility, Emergent BioSolutions aims to build healthier and safer communities. The company aspires to deliver peace of mind to theis patients and customers so they can focus on what's most important in their lives.
In working together, Emergent envisions protecting or enhancing 1 billion lives by 2030.
News
Quick info
Country
United States
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Employees
2,416
CEO
Robert Kramer
Address
400 Professional Dr Ste 400
Gaithersburg
Maryland
20879-3457
Gaithersburg
Maryland
20879-3457
Phone
12406313200
Website
www.emergentbiosolutions.com
Ticker Symbol
EBS
Exchange
New York Stock Exchange
Reporting Currency
USD
Emergent BioSolutions Inc. income statements (2022) (USD)
| August 2022 | August 2022 | April 2022 | February 2022 | |
|---|---|---|---|---|
| Total Revenue | 242.70M | 242.70M | 307.50M | 723.20M |
| Cost of Revenue | 169.80M | 169.80M | 155.90M | 212.90M |
| Gross Profit | 72.90M | 72.90M | 151.60M | 510.30M |
| Research & Development | 49.80M | 49.80M | 46.40M | 83M |
| Selling General & Admin | 81.10M | 81.10M | 84.80M | 94.20M |
| Operating Expense | 314.70M | 314.70M | 301.10M | 404.10M |
| Operating Income | -72M | -72M | 6.40M | 319.10M |
| Other Income Expense Net | 0 | 0 | 0 | 0 |
| EBIT | -72M | -72M | 6.40M | 319.10M |
| Interest Income | 7.80M | 7.80M | 8.20M | 9M |
| Pretax Income | -82.8M | -82.8M | -3.8M | 267.50M |
| Income Tax | -26.4M | -26.4M | -100K | 78.20M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -56.4M | -56.4M | -3.7M | 189.30M |
| Net Income Basic | -56.4M | -56.4M | -3.7M | 189.30M |
Emergent BioSolutions Inc. income statements (2021) (USD)
| November 2021 | July 2021 | April 2021 | February 2021 | |
|---|---|---|---|---|
| Total Revenue | 329M | 397.50M | 343M | 583M |
| Cost of Revenue | 217.50M | 227.80M | 99.30M | 168.30M |
| Gross Profit | 111.50M | 169.70M | 243.70M | 414.70M |
| Research & Development | 49.60M | 48.90M | 52.50M | 59.50M |
| Selling General & Admin | 82.10M | 91.20M | 80.90M | 82.10M |
| Operating Expense | 363.70M | 383M | 247.60M | 324.90M |
| Operating Income | -34.7M | 14.50M | 95.40M | 258.10M |
| Other Income Expense Net | 0 | 0 | 0 | 0 |
| EBIT | -34.7M | 14.50M | 95.40M | 258.10M |
| Interest Income | 8.40M | 8.60M | 8.50M | 8.70M |
| Pretax Income | -45.5M | 7.20M | 85.20M | 252.80M |
| Income Tax | -12.8M | 2.60M | 15.50M | 67.40M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -32.7M | 4.60M | 69.70M | 185.40M |
| Net Income Basic | -32.7M | 4.60M | 69.70M | 185.40M |
Emergent BioSolutions Inc. income statements (2020) (USD)
| November 2020 | June 2020 | March 2020 | |
|---|---|---|---|
| Total Revenue | 385.20M | 394.70M | 192.50M |
| Cost of Revenue | 149M | 144.80M | 91.70M |
| Gross Profit | 236.20M | 249.90M | 100.80M |
| Research & Development | 84.40M | 47.90M | 42.70M |
| Selling General & Admin | 75.50M | 76M | 69.70M |
| Operating Expense | 323.90M | 268.70M | 204.10M |
| Operating Income | 61.30M | 126M | -11.6M |
| Other Income Expense Net | 0 | -5.3M | -9.7M |
| EBIT | 61.30M | 126M | -11.6M |
| Interest Income | 7.60M | 6.40M | 8.60M |
| Pretax Income | 55M | 120.70M | -21.3M |
| Income Tax | 15.50M | 28M | -8.8M |
| Minority Interest | 0 | 0 | 0 |
| Net Income | 39.50M | 92.70M | -12.5M |
| Net Income Basic | 39.50M | 92.70M | -12.5M |
Emergent BioSolutions Inc. income statements (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Total Revenue | 360.40M | 311.80M | 243.20M | 190.60M |
| Cost of Revenue | 135.20M | 122.70M | 115.50M | 106.30M |
| Gross Profit | 225.20M | 189.10M | 127.70M | 84.30M |
| Research & Development | 62.80M | 53.40M | 63.90M | 46.10M |
| Selling General & Admin | 72.20M | 65M | 70.80M | 65.40M |
| Operating Expense | 270.20M | 241.10M | 250.20M | 217.80M |
| Operating Income | 90.20M | 70.70M | -7M | -27.2M |
| Other Income Expense Net | -18.7M | -11.8M | -8.1M | -10.6M |
| EBIT | 90.20M | 70.70M | -7M | -27.2M |
| Interest Income | 9.20M | 10.80M | 9.50M | 9.60M |
| Pretax Income | 71.50M | 58.90M | -15.1M | -37.8M |
| Income Tax | 24.60M | 15.70M | -5.6M | -11.8M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | 46.90M | 43.20M | -9.5M | -26M |
| Net Income Basic | 46.90M | 43.20M | -9.5M | -26M |
Emergent BioSolutions Inc. income statements (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Total Revenue | 270.70M | 173.65M | 220.20M | 117.81M |
| Cost of Revenue | 125.32M | 72.99M | 88.49M | 57.06M |
| Gross Profit | 145.38M | 100.66M | 131.71M | 60.76M |
| Research & Development | 52M | 37.01M | 24.75M | 29.05M |
| Selling General & Admin | 81M | 42.11M | 39.51M | 40.20M |
| Operating Expense | 258.32M | 152.10M | 152.74M | 126.31M |
| Operating Income | 12.38M | 21.55M | 67.46M | -8.5M |
| Other Income Expense Net | -8.78M | 6K | -1.64M | -0.93M |
| EBIT | 12.38M | 21.55M | 67.46M | -8.5M |
| Interest Income | 8M | 642K | 1.01M | 234K |
| Pretax Income | 3.60M | 21.56M | 65.82M | -9.42M |
| Income Tax | 7M | 614K | 15.68M | -4.52M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -3.4M | 20.95M | 50.14M | -4.91M |
| Net Income Basic | -3.4M | 20.95M | 50.14M | -4.91M |
Emergent BioSolutions Inc. income statements (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Total Revenue | 193.81M | 149.43M | 100.77M |
| Cost of Revenue | 63.78M | 43.59M | 34.39M |
| Gross Profit | 130.03M | 105.85M | 66.38M |
| Research & Development | 28.50M | 22.66M | 25.75M |
| Selling General & Admin | 41.98M | 34.50M | 31.85M |
| Operating Expense | 134.25M | 100.75M | 91.99M |
| Operating Income | 59.56M | 48.69M | 8.78M |
| Other Income Expense Net | -7.6M | -2.37M | -2.06M |
| EBIT | 59.56M | 48.69M | 8.78M |
| Interest Income | 856K | 1.28M | 1.81M |
| Pretax Income | 51.95M | 46.31M | 6.72M |
| Income Tax | 18.01M | 12.76M | 2.11M |
| Minority Interest | 0 | 0 | 0 |
| Net Income | 33.94M | 33.55M | 4.62M |
| Net Income Basic | 33.94M | 33.55M | 4.62M |
Emergent BioSolutions Inc. balance sheet (2022) (USD)
| August 2022 | August 2022 | April 2022 | February 2022 | |
|---|---|---|---|---|
| Current Cash | 358.10M | 358.10M | 435.80M | 576.10M |
| Receivables | 175M | 175M | 181.80M | 274.70M |
| Inventory | 425.50M | 425.50M | 400.70M | 350.80M |
| Current Assets | 1.08B | 1.08B | 1.10B | 1.27B |
| Other Current Assets | 125.40M | 125.40M | 81.80M | 70.30M |
| Short Term Investments | 125.40M | 125.40M | 81.80M | 70.30M |
| Long Term Investments | 1.65B | 1.65B | 1.68B | 1.69B |
| Property/Plant Equipment | 798.40M | 798.40M | 807.50M | 800.10M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 576.60M | 576.60M | 590.60M | 604.60M |
| Tangible Assets (Net) | 711.70M | 711.70M | 759.80M | 789.50M |
| Other Assets | 51.30M | 51.30M | 57.10M | 57.30M |
| Total Assets | 2.74B | 2.74B | 2.78B | 2.96B |
| Accounts Payable | 106.20M | 106.20M | 107.30M | 128.90M |
| Other Current Liabilities | 138.90M | 138.90M | 110.30M | 213.30M |
| Total Current Liabilities | 276.70M | 276.70M | 249.20M | 373.80M |
| Total Liabilities | 1.22B | 1.22B | 1.21B | 1.34B |
| Long Term Debt | 793.60M | 793.60M | 801.50M | 809.40M |
| Current Long Term Debt | 31.60M | 31.60M | 31.60M | 31.60M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 50M | 50M | 50.70M | 53.40M |
| Treasury Stock | -227.7M | -227.7M | -204.4M | -152.2M |
| Retained Earnings | 897.70M | 897.70M | 0.95B | 0.96B |
| Capital Surplus | N.A | N.A | N.A | N.A |
| Shareholder Equity | 1.51B | 1.51B | 1.58B | 1.62B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Emergent BioSolutions Inc. balance sheet (2021) (USD)
| November 2021 | July 2021 | April 2021 | February 2021 | |
|---|---|---|---|---|
| Current Cash | 403.80M | 447.50M | 547.80M | 621.30M |
| Receivables | 254.60M | 261.90M | 184.40M | 230.90M |
| Inventory | 364.60M | 386.40M | 406.50M | 307M |
| Current Assets | 1.11B | 1.16B | 1.18B | 1.20B |
| Other Current Assets | 88.30M | 66.10M | 42.20M | 36.50M |
| Short Term Investments | 88.30M | 66.10M | 42.20M | 36.50M |
| Long Term Investments | 1.76B | 1.75B | 1.72B | 1.69B |
| Property/Plant Equipment | 768.70M | 743.50M | 692.90M | 644.10M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 618.60M | 633.10M | 648.20M | 663.10M |
| Tangible Assets (Net) | 637.60M | 644M | 608.10M | 517.20M |
| Other Assets | 102.20M | 109.90M | 111.40M | 113.40M |
| Total Assets | 2.87B | 2.92B | 2.90B | 2.88B |
| Accounts Payable | 135.20M | 151.80M | 142.20M | 136.10M |
| Other Current Liabilities | 198.60M | 197.20M | 202M | 214.60M |
| Total Current Liabilities | 365.40M | 377.80M | 370.20M | 384.50M |
| Total Liabilities | 1.34B | 1.37B | 1.38B | 1.44B |
| Long Term Debt | 817.30M | 825.20M | 833.10M | 841M |
| Current Long Term Debt | 31.60M | 28.80M | 26M | 33.80M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 53.70M | 53.60M | 53.30M | 53.20M |
| Treasury Stock | -39.6M | -39.6M | -39.6M | -39.6M |
| Retained Earnings | 768.50M | 801.20M | 796.60M | 726.90M |
| Capital Surplus | N.A | N.A | N.A | N.A |
| Shareholder Equity | 1.52B | 1.54B | 1.52B | 1.45B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Emergent BioSolutions Inc. balance sheet (2020) (USD)
| November 2020 | June 2020 | March 2020 | |
|---|---|---|---|
| Current Cash | 415M | 269M | 181.70M |
| Receivables | 196.10M | 258.60M | 162.50M |
| Inventory | 270.10M | 236.20M | 248.10M |
| Current Assets | 0.96B | 755.30M | 626.60M |
| Other Current Assets | 77.40M | -8.5M | 24.10M |
| Short Term Investments | 77.40M | N.A | N.A |
| Long Term Investments | 1.66B | N.A | N.A |
| Property/Plant Equipment | 606.50M | 604.60M | 574.80M |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | 678.10M | 722.20M | 737.10M |
| Tangible Assets (Net) | 306.90M | -194.9M | -319.1M |
| Other Assets | 106.40M | 95.40M | 56.20M |
| Total Assets | 2.62B | 2.47B | 2.28B |
| Accounts Payable | 102.80M | 84.80M | 84.20M |
| Other Current Liabilities | 165.60M | 175.30M | 92.40M |
| Total Current Liabilities | 299.30M | 293.70M | 207.10M |
| Total Liabilities | 1.36B | 1.27B | 1.20B |
| Long Term Debt | 848.50M | 779.70M | 785.60M |
| Current Long Term Debt | 30.90M | 29.10M | 26.30M |
| Minority Interest | 0 | 0 | 0 |
| Common Stock | 771M | 52.90M | 52.30M |
| Treasury Stock | -39.6M | 39.60M | 39.60M |
| Retained Earnings | 541.50M | 502M | 409.30M |
| Capital Surplus | N.A | 758.50M | 726.20M |
| Shareholder Equity | 1.25B | 1.20B | 1.07B |
| Other Liabilities | N.A | N.A | N.A |
Emergent BioSolutions Inc. balance sheet (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Current Cash | 168M | 139.40M | 177.60M | 137.40M |
| Receivables | 270.70M | 281.20M | 218.10M | 121.50M |
| Inventory | 222.50M | 230.20M | 232M | 211M |
| Current Assets | 686.20M | 672.70M | 666.20M | 527.20M |
| Other Current Assets | 20.40M | 21.90M | 38.50M | 57.30M |
| Short Term Investments | N.A | N.A | N.A | N.A |
| Long Term Investments | N.A | N.A | 400K | N.A |
| Property/Plant Equipment | 567M | 548.50M | 536.20M | 526.30M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 741.90M | 768.70M | 783.40M | 798.10M |
| Tangible Assets (Net) | -298.6M | -371.6M | -417.1M | -417.3M |
| Other Assets | 52.20M | 75.30M | 66.80M | 34.40M |
| Total Assets | 2.33B | 2.33B | 2.32B | 2.15B |
| Accounts Payable | 94.80M | 91.30M | 124.50M | 78.60M |
| Other Current Liabilities | 105.10M | 171.40M | 164.70M | 157.70M |
| Total Current Liabilities | 216.30M | 275.30M | 301.20M | 248.40M |
| Total Liabilities | 1.24B | 1.30B | 1.33B | 1.17B |
| Long Term Debt | 820.50M | 830.70M | 845M | 744M |
| Current Long Term Debt | 12.90M | 10.10M | 10.10M | 10.10M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 51.70M | 51.60M | 51.60M | 51.40M |
| Treasury Stock | 39.60M | 39.70M | 39.70M | 39.60M |
| Retained Earnings | 421.80M | 374.90M | 331.70M | 341.30M |
| Capital Surplus | 716.10M | 708.80M | 701.80M | 690.20M |
| Shareholder Equity | 1.09B | 1.04B | 0.99B | 0.99B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Emergent BioSolutions Inc. balance sheet (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Current Cash | 112.40M | 340.40M | 191.28M | 164.65M |
| Receivables | 263.70M | 76.96M | 189.49M | 122.09M |
| Inventory | 205.80M | 125.75M | 139.37M | 155.20M |
| Current Assets | 620.80M | 560.25M | 541.31M | 476.65M |
| Other Current Assets | 30.30M | 17.15M | 21.17M | 27.67M |
| Short Term Investments | N.A | N.A | N.A | N.A |
| Long Term Investments | N.A | N.A | N.A | N.A |
| Property/Plant Equipment | 510.20M | 435.08M | 419.16M | 411.27M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 811.60M | 107.86M | 111.77M | 115.69M |
| Tangible Assets (Net) | 751.20M | 0.92B | 889.22M | 832.15M |
| Other Assets | 13.70M | 8.66M | 4.87M | 3.08M |
| Total Assets | 2.23B | 1.17B | 1.14B | 1.07B |
| Accounts Payable | 80.70M | 38.87M | 41.63M | 46.22M |
| Other Current Liabilities | 105.10M | 62.98M | 52.41M | 40.65M |
| Total Current Liabilities | 200.40M | 102.01M | 96.81M | 86.87M |
| Total Liabilities | 1.22B | 206.97M | 200.55M | 187.19M |
| Long Term Debt | 784.50M | 13.50M | 13.48M | 13.47M |
| Current Long Term Debt | 10.10M | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 51.20M | 50.19M | 50.01M | 49.81M |
| Treasury Stock | 39.60M | 39.64M | 39.64M | 39.64M |
| Retained Earnings | 367.30M | 370.73M | 349.78M | 299.64M |
| Capital Surplus | 688.60M | 640.18M | 632.57M | 624.48M |
| Shareholder Equity | 1.01B | 0.97B | 0.94B | 881.28M |
| Other Liabilities | N.A | N.A | N.A | N.A |
Emergent BioSolutions Inc. balance sheet (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Current Cash | 179.34M | 342.03M | 315.63M |
| Receivables | 143.65M | 129.36M | 102.51M |
| Inventory | 142.81M | 68.89M | 70.53M |
| Current Assets | 485.39M | 556.03M | 509.74M |
| Other Current Assets | 17.16M | 15.75M | 14.96M |
| Short Term Investments | N.A | N.A | N.A |
| Long Term Investments | N.A | N.A | N.A |
| Property/Plant Equipment | 407.21M | 386.46M | 380.24M |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | 119.60M | 29.20M | 30.76M |
| Tangible Assets (Net) | 662.68M | 622.71M | 579.60M |
| Other Assets | 6.05M | 6.64M | 3.72M |
| Total Assets | 1.07B | 1.02B | 0.97B |
| Accounts Payable | 41.75M | 30.11M | 29.60M |
| Other Current Liabilities | 58.32M | 43.45M | 43.32M |
| Total Current Liabilities | 100.07M | 75.43M | 72.93M |
| Total Liabilities | 157.86M | 360.49M | 349.88M |
| Long Term Debt | 13.46M | 248.99M | 248.69M |
| Current Long Term Debt | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 |
| Common Stock | 49.41M | 41.38M | 41.11M |
| Treasury Stock | 39.50M | 6.50M | 6.50M |
| Retained Earnings | 337.07M | 303.13M | 269.58M |
| Capital Surplus | 618.42M | 370.86M | 361M |
| Shareholder Equity | 0.91B | 663.71M | 620.60M |
| Other Liabilities | N.A | N.A | N.A |
Emergent BioSolutions Inc. cash flow (2022) (USD)
| November 2022 | August 2022 | |
|---|---|---|
| Net Income | -75.7M | -56.4M |
| Depreciation | 32.30M | 44.50M |
| Changes in Receivables | 191.30M | 175M |
| Changes in Inventories | 546.30M | 425.50M |
| Cash Change | 240.90M | 358.10M |
| Cash Flow | -74M | -15.6M |
| Capital Expenditures | -27.9M | -32.1M |
| Investments | N.A | N.A |
| Investing Activity (other) | N.A | N.A |
| Total Investing Cash Flows | -271.6M | -32.1M |
| Dividends Paid | N.A | N.A |
| Net Borrowings | 672.50M | 341.70M |
| Other Financing Cash Flows | N.A | N.A |
| Cash Flow Financing | 229.30M | -30.7M |
| Exchange Rate Effect | N.A | N.A |
Emergent BioSolutions Inc. cash flow (2021) (USD)
| November 2021 | |
|---|---|
| Net Income | -32.7M |
| Depreciation | 32.70M |
| Changes in Receivables | 254.60M |
| Changes in Inventories | 364.60M |
| Cash Change | 403.80M |
| Cash Flow | -32.5M |
| Capital Expenditures | -55.2M |
| Investments | N.A |
| Investing Activity (other) | N.A |
| Total Investing Cash Flows | -55.2M |
| Dividends Paid | N.A |
| Net Borrowings | 356.80M |
| Other Financing Cash Flows | N.A |
| Cash Flow Financing | -5M |
| Exchange Rate Effect | N.A |
Emergent BioSolutions Inc. cash flow (2020) (USD)
| November 2020 | June 2020 | March 2020 | |
|---|---|---|---|
| Net Income | 39.50M | 92.70M | -12.5M |
| Depreciation | 85.60M | 28.60M | 28.20M |
| Changes in Receivables | -62.5M | -96.1M | 108.20M |
| Changes in Inventories | 33.90M | 11.90M | -25.6M |
| Cash Change | 146.20M | 87.30M | 13.70M |
| Cash Flow | 290.90M | 127.90M | 57.80M |
| Capital Expenditures | -105M | -35.1M | -24.2M |
| Investments | N.A | N.A | N.A |
| Investing Activity (other) | N.A | -10M | N.A |
| Total Investing Cash Flows | -115M | -45.1M | -24.2M |
| Dividends Paid | N.A | N.A | N.A |
| Net Borrowings | 387M | -2.8M | -22.8M |
| Other Financing Cash Flows | N.A | -6.5M | -6.3M |
| Cash Flow Financing | 71.80M | 4.70M | -20M |
| Exchange Rate Effect | N.A | -200K | 100K |
Emergent BioSolutions Inc. cash flow (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Net Income | 46.90M | 43.20M | -9.5M | -26M |
| Depreciation | 27.90M | 27.70M | 28.50M | 26.60M |
| Changes in Receivables | 10.50M | -63.1M | -96.6M | 142.20M |
| Changes in Inventories | 7.70M | 1.70M | -20.9M | -5.2M |
| Cash Change | 28.60M | -38.2M | 40.20M | 25M |
| Cash Flow | 122.10M | -3.1M | -35.8M | 104.80M |
| Capital Expenditures | -36.1M | -15.3M | -14.1M | -21.4M |
| Investments | N.A | N.A | N.A | N.A |
| Investing Activity (other) | N.A | N.A | -10M | N.A |
| Total Investing Cash Flows | -36.1M | -15.3M | -24.1M | -21.4M |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | -12.9M | -17.8M | 97.20M | -52.8M |
| Other Financing Cash Flows | -47.5M | -3M | -800K | -6.5M |
| Cash Flow Financing | -57.9M | -19.7M | 100.10M | -58.4M |
| Exchange Rate Effect | 500K | N.A | N.A | N.A |
Emergent BioSolutions Inc. cash flow (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Net Income | -3.4M | 20.95M | 50.14M | -4.91M |
| Depreciation | 25.09M | 12.39M | 12.34M | 12.37M |
| Changes in Receivables | -186.75M | 112.53M | -67.4M | 21.56M |
| Changes in Inventories | -18.97M | 13.63M | 15.82M | -12.38M |
| Cash Change | -227.97M | 149.12M | 26.63M | -14.69M |
| Cash Flow | -165.76M | 173.97M | 34.58M | -0.99M |
| Capital Expenditures | -20.83M | -26.06M | -13.6M | -11.62M |
| Investments | N.A | N.A | N.A | N.A |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | -848.55M | -26.06M | -10.98M | -11.62M |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | 781.80M | N.A | N.A | N.A |
| Other Financing Cash Flows | -363K | -1.26M | -604K | -6.67M |
| Cash Flow Financing | 785.98M | 1.68M | 3.17M | -2.13M |
| Exchange Rate Effect | 367K | -471K | -141K | 45K |
Emergent BioSolutions Inc. cash flow (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Net Income | 33.94M | 33.55M | 4.62M |
| Depreciation | 12.67M | 9.80M | 9.93M |
| Changes in Receivables | -14.3M | -26.85M | 25.57M |
| Changes in Inventories | 0.95M | 1.64M | 203K |
| Cash Change | -161.66M | 25.36M | 45.46M |
| Cash Flow | 78.95M | 33.52M | 54M |
| Capital Expenditures | -12.45M | -12.78M | -9.3M |
| Investments | N.A | N.A | N.A |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | -207.55M | -12.78M | -9.3M |
| Dividends Paid | N.A | N.A | N.A |
| Net Borrowings | N.A | N.A | N.A |
| Other Financing Cash Flows | -7.23M | -1.51M | -881K |
| Cash Flow Financing | -33.1M | 4.69M | 765K |
| Exchange Rate Effect | 47K | -62K | -9K |
Emergent BioSolutions Inc. dividends (USD)
Total Valuation
Emergent Biosolutions Inc has a market cap or net worth of $406.14 million. The enterprise value is $1.17 billion.
Market Cap
406.14M
Enterprise Value
1.17B
Important Dates
Earnings Date
Apr 27, 2023
Ex-Dividend Date
n.a
Share Statistics
Emergent Biosolutions Inc has 50.14 million shares outstanding.
Shares Outstanding
50.14M
Float
n.a
Valuation Ratios
The trailing PE ratio is -1.8147 and the forward PE ratio is -9.5070. Emergent Biosolutions Inc's PEG ratio is 0.0089.
PE Ratio
-1.8147
Forward PE
-9.5070
PS Ratio
0.3623
PB Ratio
0.2937
PEG Ratio
0.0089
Stock Price Statistics
The stock price has decreased by -0.3141%. The beta is 1.7087, so Emergent Biosolutions Inc's price volatility has been higher than the market average.
Beta (1Y)
1.7087
52-Week Price Change
-0.3141%
50-Day Moving Average
11.64
200-Day Moving Average
14.98
Average Volume (30 Days)
1.53M
Income Statement
In the last 12 months, Emergent Biosolutions Inc had revenue of $1.12 billion and earned $427.20 million in profits. Earnings per share was $-4.47.
Revenue
1.12B
Gross Profit
427.20M
EBITDA
-106.1M
Earnings per Share
-4.47
About
Ticker Symbol
EBS
Reporting Currency
USD
Key Executives
Kramer Robert
Interim, EVP, BioSciences
Elsey R Don
CFO
Abdun-Nabi Daniel
CEO & President
Kirk Sean
EVP, Manufacturing & Tech Ops
Keese Kyle
SVP, BioSciences Division
El-Hibri Fuad
Chairman & CEO